Barclays Raises UiPath (NYSE:PATH) Price Target to $17.00

UiPath (NYSE:PATH – Get Rating) had its target price hoisted by Barclays from $13.00 to $17.00 in a research note published on Thursday, The Fly reports. They currently have an equal weight rating on the healthcare company’s stock.

A number of other analysts also recently commented on the stock. Credit Suisse Group decreased their price objective on shares of UiPath from $30.00 to $27.50 and set an outperform rating on the stock in a report on Wednesday, November 16th. Royal Bank of Canada restated a sector perform rating and set a $15.00 target price on shares of UiPath in a research report on Monday, March 13th. JPMorgan Chase & Co. cut their target price on shares of UiPath from $18.00 to $16.00 and set a neutral rating for the company in a research report on Friday, December 2nd. Evercore ISI cut their target price on shares of UiPath to $17.00 in a research report on Friday, December 2nd. Finally, Truist Financial cut their target price on shares of UiPath from $25.00 to $20.00 and set a buy rating for the company in a research report on Friday, December 2nd. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, UiPath presently has an average rating of Hold and an average target price of $19.19.

UiPath Price Performance

PATH stock opened at $17.05 on Thursday. UiPath has a 52 week low of $10.40 and a 52 week high of $31.88. The company’s 50-day moving average price is $15.06 and its 200 day moving average price is $13.60.

Insider Buying and Selling

In related news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $16.61, for a total transaction of $664,400.00. Following the completion of the transaction, the chief financial officer now owns 1,359,051 shares of the company’s stock, valued at $22,573,837.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 31.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On UiPath

Several institutional investors and hedge funds have recently bought and sold shares of PATH. Raymond James Financial Services Advisors Inc. increased its position in UiPath by 3.8% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 40,993 shares of the healthcare company’s stock worth $885,000 after purchasing an additional 1,506 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in UiPath during the first quarter worth approximately $184,000. BlackRock Inc. grew its stake in UiPath by 1.9% during the first quarter. BlackRock Inc. now owns 5,316,635 shares of the healthcare company’s stock worth $114,786,000 after buying an additional 99,242 shares during the period. Dimensional Fund Advisors LP purchased a new stake in UiPath during the first quarter worth approximately $534,000. Finally, Canada Pension Plan Investment Board purchased a new stake in UiPath during the first quarter worth approximately $259,000. Institutional investors and hedge funds own 56.40% of the company’s stock.

UiPath Company Profile

(Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.